ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY, BIOMARKER DEVELOPMENT & AGING RESEARCH
Our Mission is to extend healthy longevity through innovative AI solutions for drug discovery and aging research.
We aspire to be a leader in the field of deep learning for drug discovery, personalized healthcare, and anti-aging interventions.
AI Pharma Pipeline
We developed a comprehensive drug discovery engine, which utilizes millions of samples and multiple data types to discover signatures of disease and identify the most promising targets for billions of molecules that already exist or can be generated de novo with the desired set of parameters.
Integrated top-down and bottom-up target ID and drug discovery pipelines
Pharmaceutical Pipeline Leads
Nutraceutical Pipeline Leads
Services & Collaborations
We provide services to academia, pharmaceutical and cosmetics companies:
Advanced deep learning solutions
Custom drug discovery engines
Custom biomarkers discovery
New tools for aging research
Bridging the pharmaceutical and consumer industries
Awards & Recognition
We will provide customers with the industry-leading services, based on our extensive experience and proven track-record in innovative computational technology
Technology leadership in artificial intelligence for drug discovery and biomarker development, academic excellence, extensive collaborations with pharmaceutical and consumer companies, novel methods of attracting top talent, and increasing global reach have allowed Insilico Medicine to build a credible and sustainable business model in the nascent longevity biotechnology industry," noted Neelotpal Goswami. "In recognition of its pioneering research and ability to introduce novel products and solutions for age management, Frost & Sullivan is pleased to present it with the 2018 Technology Innovation Award".
Videos about Insilico Medicine
Pioneers'18 - Artificial Intelligence for Healthy Longevity
2018 AI 100 Startup: Insilico
Geroprotect Partnership Between Life Extension and Insilico Medicine
About Insilico Medicine
Embryonic AI: Analysis of Embryonic State using Deep Neural Networks (Property of Biotime, Inc)
Our youtube channel
Some of Our Current Projects
Insilico Medicine is committed to transforming the pharmaceutical industry with next-generation artificial intelligence. We are developing new tools for drug discovery and repurposing, biomarker development and pursuing novel strategies for rapid validation. Our projects combine advances in genomics, big-data analysis, deep learning and reinforcement learning.
Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specialized in the application of deep learning for target identification, drug discovery and aging research, announced that it has entered into a collaboration agreement with WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company.
Insilico Medicine, a company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its CEO, Alex Zhavoronkov, at the Pioneers 18 Conference, May 25, 2018, Vienna, Austria.
Oct. 30, 2017, London, UK: Biogerontology Research Foundation (bg-rf.org.uk) Chief Science Officer, Dr. Alex Zhavoronkov and Biogerontology Research Foundation Advisor and Head of Business Development for Juvenescence …
Insilico Medicine, a leader in the field of artificial intelligence, will present at the Singularity University Exponential Medicine Program in San Diego on Wednesday November 8 in Session XVIII - Future of Pharma
Our team is formed of bioinformatics, computational and structural biology experts, experienced medicinal chemists and deep learning engineers, who work with massive biomedical data and practical problems in drug discovery.
Alex Zhavoronkov, PhD
Qingsong Zhu, PhD
President of EMEA
Marine Bozdaganyan, PhD
Head of Medicinal Chemistry
Ivan Ozerov, PhD
Director, Drug Discovery
Quentin Vanhaelen, PhD
Director, Virtual Human Project
We have 45 scientists hired through hackathons and competitions worldwide in the US, UK, Poland, Belgium, South Korea, Taiwan, Africa and Russia.
Scientific Advisory Board
Charles Cantor, PhD
ex-Director of the Human Genome Project and the Center for Advanced Biotechnology at Boston University
Michael Levitt, PhD
2013 Nobel Laureate (Chemistry) Professor, Stanford University
Bud Mishra, PhD
Professor of computer science at Courant Institute, professor of biology at Mt. Sinai School of Medicine and NYU School of Medicine
Donald Small, MD, PhD
Director of pediatric oncology at the Johns Hopkins Kimmel Cancer Center
Yuri Nikolsky, PhD
Co-founder, GeneGo, ex-VP Thomson Reuters Director, Skolkovo Found
Kristen Fortney, PhD
CEO, BioAge. Postdoctoral fellow of Ellison Medical Foundation/American Federation for Aging Research at Stanford University
Alexey Moskalev, PhD
Professor at Syktyvkar State University Head of the laboratory of Molecular radiobiology and gerontology at the Institute of biology of Komi Science Center of Ural division of RAS
Ulrich Muehlner, PhD
Founder at GrowthCube Partners Previously Director Global Corporate Strategy at Novartis and with The Boston Consulting Group (BCG)
Insilico Medicine, a Baltimore-based next-generation AI company specializing in the application of deep learning for target identification, drug discovery and aging research, yesterday announced a collaboration agreement with WuXi AppTec...
Nvidia is on a quest to find the best "social impact" artificial intelligence startups as part of a program called Nvidia Inception, which is screening more than 600 entrants to cull the best AI startups in three big categories.